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Delirium: assessment and treatment in the patient with cancer PART 2 
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Abstract 
Delirium at the end of life may present significant ethical dilemmas in clinical practice: whether to 
simply treat it in order to maximise symptom relief, with the resulting side effect being palliative 
sedation, or to attempt to reverse delirium and risk prolonging suffering. Determining whether the 
delirium can be reversed involves comprehensive assessment using established tools, which may or 
may not provide the answer to the question posed. This article examines the evidence surrounding 
several assessment tools that have  been suggested as effective in identifying delirium, and the 
consequences of various approaches to the management of delirium in a patient with a cancer 
diagnosis. It also considers the impact delirium may have on the health professional and those close 
to the patient. 
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There is an abundance of assessment tools available that are specifically designed to recognise the 
onset of delirium (Pisani, 2015). It might be considered, therefore, that delirium should be easily 
recognised. 
As discussed in part 1 (Hardy and Brown, 2015), this is not, in fact, the case. Delirium may present 
alonside a diverse range of symptoms, which can confuse health professionals in identifying its cause 
and it also presents with traits extremely similar to that of dementia (Weinrich and Sarna, 2006; 
National Institute for Health and Care Excellence (NICE), 2010). 
Discussion of assessment and management of delirium has primarily focused on the elderly with 
predisposing infection or patients that are in the immediate post-operative phase (Weinrich and 
Sarna, 2006).There are a number of questions surrounding management of delirium (also referred to 
as acute confusional state) but delirium at the end of life may be a separate entity—a suggestion 
lent weight by the fact that NICE (2010) specifically omits end-of-life delirium from its guidelines and 
pathways. 
There appear to be two clear approaches to managing delirium for cancer patients at the end of life. 
One encompasses attempts to reverse and treat the pre-disposing factors, such as constipation and 
infection, followed by the use of gentle antipsychotics if the delirium is unresolved. The other is the 
use of medications to ensure the relief of distress, but without purposeful sedation. 
Delirium-focused assessment tools may be under-used in clinical environments but could present a 
solution to managing the symptoms of delirium. Issues surrounding the use of any tool include when 
to apply it, The optimal frequency for assessment of delirium and whether it should be repeated 
(Pisani,2015). There are several tools available but choosing the most appropriate one for use in 
palliative care could prove difficult. 
Following the recognition of delirium, treatment should be instigated but this may also present 
significant clinical dilemmas and issues for the patient, the family and the health professional 
involved. Ensuring that the patient is at the centre of all decision making should be the priority, 
allowing them to make choices regarding end-of-life treatment, which includes palliative sedation 
(Department of Health (DH), 2008). 
 
Assessment tools 
The Mini Mental State Examination tool (MMSE) is one assessment tool that could be used to help in 
the diagnosis of delirium at the end of life for cancer patients. It is a simple test that could be used 
for all high-risk patients and may help distinguish early stages of confusion. The MMSE is primarily 
used as an initial screening tool when assessing a patient’s ability to make decisions. This is followed 
by a more comprehensive tool completed by trained professional raters. What must be considered 
when using this tool is that the patient completes simple arithmetic and needs to be able to read 
and write—it is not uncommon to interact with patients who may find this difficult owing to 
established disabilities, or people that do not have English as their first language (Weinrich and 
Sarna, 2006). This may affect the validity of the outcome.However,it could be argued that the rater 
should be trained to assess for such variables. 
To ensure that assessment tools are appropriate for use they are measured against the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) (Brown and Degner,2001),which was initially 
developed in 1952.The purpose of the DSM is to provide a baseline for the standard criteria of any 
diagnostic tool (Trzepacz et al, 2001). The previous edition, DSM 4, was reviewed and criticised for 
its lack of scientific evidence but praised for helping to standardise the diagnosis of psychiatric 
conditions (Marshall et al, 1999). The latest edition, DSM 5, has been significantly revised as a whole; 
it has been developed by using research and statistical data from hospital environments.With the 
DSM5 now in use, it may mean that the tool is more reliable and/or easy to use which will help to 
improve the assessment quality. 
The Confusion Assessment Method (CAM) is another assessment tool that may be adopted for the 
assessment of delirium in the terminal phase of life (Brown and Degner, 2001). It has been tested for 
validity and reliability, scoring in the range of 90-100% for accuracy in sensitivity and specificity 
(Meagher et al, 2001;Waszynski, 2004) and found to correlate well with the DSM 4 and MMSE, but 
does not assess for severity of symptoms (Brown and Degner, 2001; Waszynski, 2004).This tool is 
effective for patients with terminal delirium as it is brief, therefore giving prompt indication of 
delirium (Brown and Degner, 2001;Waszynski, 2004). 
The Delirium Rating Scale-1998 (DRS-98) was initially designed for the assessment of delirium in a 
variety of diagnostic cases and was developed byTrzepacz in 1988.This tool has since been 
established as an effective tool for use in the assessment of delirium in patients at the end of life 
(Brown and Degner, 2001). The DRS-98 is time consuming as it requires consideration of past 
medical history, nursing observations, tests and patient interviews, it is for this reason that extra 
training may be required to complete the assessment.When comparing the DSM-98 with other tools, 
for example the CAM, although CAM is quicker and relatively simplistic, it only assesses for actual 
symptoms and not the severity of symptoms whereas the DRS-98 does assess for severity, but its 
drawback is the complexity, and it has been found difficult to use for reassessment throughout an 
episode of delirium (Trzepacz et al, 2001). It could be concluded that the poor efficacy of delirium 
assessment tools is multi-factorial. Inconsistency of assessment is a major aspect as no one tool 
encompasses all arenas of delirium so it may require the use of more than one tool to accurately 
recognise, assess and treat the onset of delirium for a cancer patient at the end of life. Although the 
tools have been identified as useful in assessing for delirium, identifying the severity is deficient in 
many cases. To aid effective management of patients presenting with delirium, information and 
advice surrounding treatment of the delirium would help and ascertaining whether it is reversible 
would undoubtedly expedite patient treatment as one could focus on treatment rather than type of 
delirium.This may help to ensure individuals receive appropriate treatment and reverse the delirium 
providing there is time to reverse the presentation. Delirium at the end of life carries other issues, 
one of which is ethical debate about suffering whilst waiting for full assessment and treatment 
initiation.  
 
 
Ethical considerations: the use of medication when managing delirium 
Evidence-based practice is a requirement in nursing practice (Nursing and Midwifery Council, 2015) 
however, the majority of the evidence base to date appears to focus on general adult nursing care 
and does not specifically relate to delirium at the end of life for a cancer patient .The need to 
identify reversibility remains important in end-of-life care (Twycross, 1997; Payne and Turner, 2008 
NICE 2015), but in certain cases, e.g. where death is imminent, it may be that addressing reversible 
causes may prove inappropriate. Deciding if the delirium is reversible or irreversible alone can be an 
ethical dilemma as valuable time may be wasted during the investigation and Whilst potentially 
leaving the patient suffering. Where time is limited and success unrealistic then one may suggest 
that controlling should be the practitioners goal. There are recommendations and suggestions within 
the literature (Regnard and Kindlen, 2002; Payne et al, 2004): the need to ensure the patient is 
orientated to day, time and place, facilitation of distraction therapy and, if necessary the use of 
medication. 
A search of the Cochrane reviews for evidence to support medication selection reveals there is still a 
lack of specific treatments for specific patient presentations (Siddiqi et al, 2007; Lonergan et 
al,2007;Overshott et al,2008;Lonergan et al,2009). The systematic reviews report insufficient 
evidence to suggest efficacious regimes, especially in end-of-life care. They have identified that the 
use of benzodiazepines or antipsychotics for delirium should be administered with caution as the 
effects of the drug can differ greatly depending on the cause of delirium (Meagher and Leonard, 
2008). A general side effect of some antipsychotics and benzodiazepines is sedation. In clinical 
practice it has been suggested that this side effect may be of some benefit alongside treatment of 
the delirium for patients with the refractory symptoms of delirium, often referred to as palliative 
sedation (Payne et al, 2004) but the use of palliative sedation may be rejected in many areas offering 
palliative care to patients due to the ethical dilemmas involved—especially in light of the review of 
the Liverpool Care Pathway, which found sedation and opiate analgesia being used inappropriately 
in some cases (Neuberger et al, 2013). 
Palliative sedation alone presents ethical dilemmas, but a pertinent issue that must be discussed is 
how people perceive palliative sedation. It is considered by some to be an indirect form of 
euthanasia (Payne et al, 2004; Rietjens et al, 2009). In Rietjen et al’s (2009) study doctors in the 
Netherlands who had experience caring for patients at the end of life answered questions regarding 
how they responded to patients’ suffering from refractory symptoms. The majority reported that 
they would be happy to administer palliative sedation to patients within the last hours of life. But 
when they were asked if they would consider this intervention to those in the last weeks/days of life, 
a debate was initiated as they queried how to predict if a patient was in the last weeks of life. 
Full and frank discussion with patients approaching the end of life or those who have advanced life-
limiting disease may help to alleviate and clarify these ethical dilemmas regarding treatment by 
involving them in the decisions surrounding sedation at the end of life. It is also important to try to 
use other methods of managing delirium before resorting to sedation.Keeping patients 
involved,empowering and facilitating autonomy is fundamental to health service provision and has 
been highlighted as a significant goal in high-quality end-of-life care (NICE, 2004; NICE, 2011; DH, 
2008; Brown andVaughan, 2013; NMC, 2015). 
There are arguments for and against the use of medication to manage delirium, but it appears the 
fundamental issues lie with the ability to diagnose the form of delirium the patient is suffering from. 
Once this has been established it is possible to attempt treatment or begin reversing the symptoms 
(Leonard et al, 2008), but the ethical dilemma at the end of life rests on continuing to do this or 
focusing on comfort and quality of life (Leonard et al, 2008). It may be that making the patient 
comfortable at the end of life could be achieved more quickly than identifying and treating the 
cause.  
Impact of delirium on the family 
It must be acknowledged that,alongside the distress that delirium can cause to the patient and the 
nursing team trying to manage the symptoms, the family and patient’s loved ones also report 
increased anguish and despair (Morita et al, 2007).The National End of Life Care Strategy (DH, 2008) 
was initiated to promote high-quality end-of-life care and heighten health professionals’ 
awareness.What it did not specifically do was refer to the needs of the family when symptoms are 
perceived as distressing,such as pain, nausea and vomiting or delirium (DH, 2009; 2011; Smith et al, 
2012). Although there may be some issues surrounding diagnosis of terminal delirium or agitation, it 
continues to be reported as a common complication at the end of life for cancer patients (Morita et 
al, 2007). Morita et al (2007) approached 560 bereaved family members of cancer patients who 
developed delirium during the last 2 weeks of life and this resulted in 402 responses (75% response 
rate). The Japanese study specifically reviewed the impact of delirium from the families’ perspective. 
They reported significant issues such as the family feeling a failure at a critical time when they think 
they should be strong for their loved one.Those who were bereaved admitted to being very 
distressed watching their loved ones suffer with delirium and felt that professional care was lacking 
in managing this symptom (Morita et al, 2007). Bruera et al’s (2009) study of bereaved relatives who 
reported delirium in their loved ones concurred and identified that family members suffered high 
levels of stress when recalling the symptoms of delirium. Interestingly, the researchers noted that 
family or caregivers reported more symptoms of delirium such as groaning, restless movement and 
shouting, than the specialist palliative care nurses (Bruera et al, 2009).A rationale for the difference 
in the number of symptoms reported by family in comparison to the nurses was that they believed 
family members over-interpret what they are witnessing, allowing their personal anxieties to affect 
their recall (Bruera et al, 2009).The nurse’s recall of a patient’s experience of delirium, however, was 
not included within the results of this study. 
 
High-quality care at the end of life for patients with cancer: guidance and evidence 
What is evident is that delirium is a significant symptom for patients at the end of life with cancer. It 
is also clear that the complex variances that manifest themselves within delirium are often difficult 
to recognise and manage. Although delirium is recognised as a problem there is very little national 
guidance to aid effective management on a nursing level for patients at the end of life. Despite this, 
there have been a number of policies released, aimed at enhancing quality of life for cancer patients 
(NICE, 2004; DH, 2008). 
  
A significant policy document was the Policy Framework for Commissioning Cancer Services (The 
Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995) 
commonly referred to as the ‘Calman Hine Report.’ This identified that the government must 
implement a number of national standards to enhance the care received by patients who have 
cancer.Although the report predominantly focused on how to avoid advanced cancer diagnoses by 
using early detection and prevention strategies, rather than how to care for people with advanced 
cancer, it can be argued that it also laid the foundations for the governments’ dedication to focus on 
the care that people with cancer receive (NHS, 2004, NICE, 2004, NICE 2011).  
Evidence of this can be seen in the release of The End of Life Care Strategy (DH, 2008), which was 
primarily introduced to ensure quality care at the end of life.An outcome of the strategy was the 
adoption of the ‘Liverpool Care Pathway’ by numerous healthcare providers. This model of care was 
introduced as a tool to ensure that all arenas of healthcare delivering palliative care were able to 
meet the hospice model of care ,which was deemed the ‘gold standard’ (DH, 2008). It has 
subsequently received significant criticism, and its use has been abandoned, the principles for high-
quality care for those approaching end of life remain undeniable (Neuberger et al, 2013). 
 
 
Conclusion 
The diagnosis of delirium may be facilitated by adopting a specific assessment tool. There are many 
tools available and what has been apparent is that each tool can effectively aid the diagnosis of 
delirium but, each tool has some degree of limitation. Primarily, the specifically designed tools 
required the rater to be trained in its use or they contained a significant number of questions or 
activities which may aggravate the patient more if delirium is present.The use of a tool may prove 
beneficial in diagnosing delirium, but when other comorbidities exist, e.g. dementia or depression, 
the efficacy of the tool may be  compromised. 
Practice requires development on a local and national level to ensure that every patient receives 
high-quality evidence-based nursing care when dealing with symptoms at the end of life. 
Delirium at the end of life is a distressing symptom, but when compared to other symptoms,which 
may also be distressing,little research has been done to ascertain best practice in its management. It 
is clear that work is continually being carried out to understand more about delirium, but 
unfortunately, end-of-life care requires a more focused approach and the research appears 
generalised. 
A number of assessment tools have been examined but there appears to be little agreement among 
researchers about which one would be effective. It was suggested that the combination of two or 
three tools would accurately diagnose delirium, but this could be time consuming and onerous, 
exhausting the patient with questions and at times initiate inappropriate interventions. Delirium 
remains largely understudied with little reliable and validated research to clearly suggest and 
implement best practice. 
Delirium can have significant impact not only on the patient experience but that of carers and loved 
ones. Identifying the need for intervention and providing a supportive network for all involved 
should be part of the holistic approach to care at the end of life. It is hoped that this discussion has 
provided those nursing patients at the end of life with some understanding surrounding the 
recognition, managment and treatment of delirium. More importantly it is hoped that this work will 
encourage and enthuse researchers to commence a pathway of evidence based management of 
delirium at the end of life for a cancer patient.  
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